SCHEMBL4027635

SCHEMBL4027635

CN(C)C(=O)C=Cc1ccc2noc(-c3ccc(Cl)cc3)c2c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 11/20 0.79
IP6K2 Q9UHH9 10/20 0.79
ALDH1A1 P00352 8/20 0.62
MAPT P10636 4/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
POLB P06746 3/20 0.62
KDM4E B2RXH2 3/20 0.62
IP6K3 Q96PC2 9/20 0.61
HTT P42858 2/20 0.59
LMNA P02545 2/20 0.59
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
HPGD P15428 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
PTK2B Q14289 1/20 0.50
GFER P55789 1/20 0.50
HSP90AA1 P07900 1/20 0.47
GAA P10253 1/20 0.47
TBK1 Q9UHD2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4027321 0.89 IP6K1 (0.79) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL4031543 0.89 IP6K1 (0.79) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL25990105 0.88 IP6K1 (1.00) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL4034482 0.88 IP6K1 (1.00) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL25990191 0.76 IP6K1 (1.00) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL4027637 0.75 POLB (0.81) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL30967410 0.75 IP6K1 (1.00) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL25990260 0.75 IP6K1 (1.00) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL2505119 0.74 ALDH1A1 (0.69) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2
SCHEMBL2505118 0.74 ALDH1A1 (0.69) IP6K1IP6K2ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399440-B1 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2009-06-03 EP disclosed
US-20050228005-A1 Protein kinase inhibitors and uses thereof MOON YOUNG C 2005-10-13 US disclosed
US-6825190-B2 4-(1,2- OR 2,1-BENZOXAZOL-5-YL)-2-AMINOPYRIMIDINES VERTEX PHARMACEUTICALS INCORPORATED 2004-11-30 US disclosed
US-20040009996-A1 Protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009996-A1 Protein kinase inhibitors and uses thereof GSK3A, GSK3B, JAK3 IP6K1 278/4885IP6K2 334/4885ALDH1A1 1993/4885
US-20050228005-A1 Protein kinase inhibitors and uses thereof GSK3A, JAK3, GSK3B IP6K1 363/4885IP6K2 400/4885ALDH1A1 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.